Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study
in Beneficial MicrobesSearch for other papers by K. Preston in
Current site
Google Scholar
Search for other papers by R. Krumian in
Current site
Google Scholar
Search for other papers by J. Hattner in
Current site
Google Scholar
Search for other papers by D. de Montigny in
Current site
Google Scholar
Search for other papers by M. Stewart in
Current site
Google Scholar
Search for other papers by S. Gaddam in
Current site
Google Scholar
A combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 was compared to placebo for relief of symptoms of irritable bowel syndrome (IBS). A total of 113 subjects at 3 clinical sites were randomised in a 2:1 ratio and followed for 12 weeks. Subjects ingested either 2 capsules of active study product, containing 50×109 cfu of live organisms, or 2 placebo capsules daily. Endpoints included improvement in abdominal pain, days of pain, distention, stool consistency and frequency, quality of life (QOL), and adequate relief (AR) of IBS symptoms. IBS subtypes constipation (IBS-C), diarrhoea (IBS-D), and mixed (IBS-M) were evaluated separately; the effect of gender was also examined. For all efficacy endpoints improvement of 30% or more vs placebo was considered clinically significant. With the exception of pain intensity and AR, the endpoints demonstrated a therapeutic advantage of active over placebo for IBS symptoms in at least some subject subgroups. The IBS-D and female subgroups showed the largest and most consistent effects. Stool frequency and consistency were evaluated in the IBS-C and IBS-D subgroups, and improvement of active vs placebo was noted in both. QOL improvement was seen overall and in specific domains. Adverse events (AEs) were limited to 7 subjects; all were of mild or moderate intensity except one, severe cramping. Four AEs in the same subject in the placebo group were judged to be related to study product; these resolved by the end of study. There were no serious AEs.
Kauf
Sofortzugang erwerben (PDF-Download und unbegrenzter Online-Zugang):
Institutszugang
Melden Sie sich mit Open Athens, Shibboleth oder Ihren institutionellen Anmeldedaten an.
Persönliche Anmeldung
Melden Sie sich mit Ihrem brill.com-Konto an
-
Aagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., Patel, S., Cutting, M., Madden, T., Hamilton, H., Harris, E., Gevers, D., Simone, G., McInnes, P. and Versalovic, J., 2013. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB Journal 27: 1012-1022.
'The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters ' () 27 FASEB Journal : 1012 -1022.
-
Auclair, J., Frappier, M. and Millette, M., 2015. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clinical Infectious Diseases 60, Suppl. 2: S135-S143.
'Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection ' () 2 Clinical Infectious Diseases : S135 -S143.
-
Beausoleil, M., Fortier, N., Guénette, S., L’ecuyer, A., Savoie, M., Franco, M., Lachaine, J. and Weiss, K., 2007. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Canadian Journal of Gastroenterology 21: 732-736.
'Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial ' () 21 Canadian Journal of Gastroenterology : 732 -736.
-
Camilleri, M., Mayer, E.A., Drossman, D.A., Heath, A., Dukes, G.E., McSorley, D., Kong, S., Mangel, A.W. and Northcutt, A.R., 1999. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Alimentary Pharmacology and Therapeutics 13: 1149-1159.
'Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist ' () 13 Alimentary Pharmacology and Therapeutics : 1149 -1159.
-
Coffin, B., Dapoigny, M., Cloarec, D., Comet, D. and Dyard, F., 2004. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroentérologie Clinique et Biologique 28: 11-15.
'Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome ' () 28 Gastroentérologie Clinique et Biologique : 11 -15.
-
Cremonini, F., Delgado-Aros, S. and Camilleri, M., 2003. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterology and Motility 15: 79-86.
'Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials ' () 15 Neurogastroenterology and Motility : 79 -86.
-
Drossman, D.A., Patrick, D.L., Whitehead, W.E., Toner, B.B., Diamant, N.E., Hu, Y., Jia, H. and Bangdiwala, S.I., 2000. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. American Journal of Gastroenteroloy 95: 999-1007.
'Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire ' () 95 American Journal of Gastroenteroloy : 999 -1007.
-
Ducrotté, P., Sawant, P. and Jayanthi, V., 2012. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology 18: 4012-4018.
'Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome ' () 18 World Journal of Gastroenterology : 4012 -4018.
-
Fava, F., Gitau, R., Griffin, B.A., Gibson, G.R., Tuohy, K.M. and Lovegrove, J.A., 2013. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population. International Journal of Obesity 37: 216-223.
'The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population ' () 37 International Journal of Obesity : 216 -223.
-
Ford, A.C. and Moayyedi, P., 2010. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 32: 144-158.
'Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome ' () 32 Alimentary Pharmacology and Therapeutics : 144 -158.
-
Ford, A.C., Quigley, E.M., Lacy, B.E., Lembo, A.J., Saito, Y.A., Schiller, L.R., Soffer, E.E., Spiegel, B.M. and Moayyedi, P., 2014a. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. American Journal of Gastroenterology 109: 1350-1365.
'Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis ' () 109 American Journal of Gastroenterology : 1350 -1365.
-
Ford, A.C., Quigley, E.M., Lacy, B.E., Lembo, A.J., Saito, Y.A., Schiller, L.R., Soffer, E.E., Spiegel, B.M. and Moayyedi, P., 2014b. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. American Journal of Gastroenterology 109: 1547-1561.
'Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis ' () 109 American Journal of Gastroenterology : 1547 -1561.
-
Foxx-Orenstein, A., 2006. IBS – review and what’s new. Medscape General Medicine 8: 20.
'IBS – review and what’s new ' () 8 Medscape General Medicine : 20.
-
Gao, X.W., Mubasher, M., Fang, C.Y., Reifer, C. and Miller, L.E., 2010. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. American Journal of Gastroenterology 105: 1636-1641.
'Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients ' () 105 American Journal of Gastroenterology : 1636 -1641.
-
Guglielmetti, S., Mora, D., Gschwender, M. and Popp, K., 2011. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics 33: 1123-1132.
'Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study ' () 33 Alimentary Pharmacology and Therapeutics : 1123 -1132.
-
Halpern, G.M., Prindiville, T., Blankenburg, M., Hsia, T. and Gershwin, M.E., 1996. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. American Journal of Gastroenterology 91: 1579-1585.
'Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial ' () 91 American Journal of Gastroenterology : 1579 -1585.
-
Hoveyda, N., Heneghan, C., Mahtani, K.R., Perera, R., Roberts, N. and Glasziou, P., 2009. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology 9: 15.
'A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome ' () 9 BMC Gastroenterology : 15.
-
Hughes, V., 2012. Microbiome: cultural differences. Nature 492: S14-S15.
'Microbiome: cultural differences ' () 492 Nature : S14 -S15.
-
Kajander, K., Myllyluoma, E., Rajilić-Stojanović, M., Kyronpalo, S., Rasmussen, M., Järvenpää, S., Zoetendal, E.G. De Vos, W.M., Vapaatalo, H. and Korpela, R., 2008. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology and Therapeutics 27: 48-57.
'Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota ' () 27 Alimentary Pharmacology and Therapeutics : 48 -57.
-
Kellow, J., Lee, O.Y., Chang, F.Y., Thongsawat, S., Mazlam, M.Z., Yuen, H., Gwee, K.A., Bak, Y.T., Jones, J. and Wagner, A., 2003. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52: 671-676.
'An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome ' () 52 Gut : 671 -676.
-
Kim, H.J., Camilleri, M., McKinzie, S., Lempke, M.B., Burton, D.D., Thomforde, G.M. and Zinsmeister, A.R., 2003. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 17: 895-904.
'A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome ' () 17 Alimentary Pharmacology and Therapeutics : 895 -904.
-
Lorenzo-Zúñiga, V., Llop, E., Suárez, C., Alvarez, B., Abreu, L., Espadaler, J. and Serra, J., 2014. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World Journal of Gastroenterology 20: 8709-8716.
'I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life ' () 20 World Journal of Gastroenterology : 8709 -8716.
-
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A.C. and Veijola, L., 2016. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World Journal of Gastroenterology 22: 10631-10642.
'Irritable bowel syndrome symptom severity improves equally with probiotic and placebo ' () 22 World Journal of Gastroenterology : 10631 -10642.
-
Maziade, P.J., Pereira, P. and Goldstein, E.J., 2015. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clinical Infectious Diseases 60, Suppl. 2: S144-147.
'A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+) ' () 2 Clinical Infectious Diseases : S144 -147.
-
McFarland, L.V. and Dublin, S., 2008. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World Journal of Gastroenterology 14: 2650-2661.
'Meta-analysis of probiotics for the treatment of irritable bowel syndrome ' () 14 World Journal of Gastroenterology : 2650 -2661.
-
Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., La Ferla, B., Schiano, I., Michelotti, A., Nobile, V., Labra, M. and Di Gennaro, P., 2016. A randomized, double-blind, placebo-controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. BioMed Research International 2016: 4740907.
'A randomized, double-blind, placebo-controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation ' () 2016 BioMed Research International : 4740907.
-
Moayyedi, P., Ford, A.C., Talley, N.J., Cremonini, F., Foxx-Orenstein, A.E., Brandt, L.J. and Quigley, E.M., 2010. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325-332.
'The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review ' () 59 Gut : 325 -332.
-
Niv, E., Naftali, T., Hallak, R. and Vaisman, N., 2005. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clinical Nutrition 24: 925-931.
'The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study ' () 24 Clinical Nutrition : 925 -931.
-
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F. and Quigley, E.M., 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551.
'Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles ' () 128 Gastroenterology : 541 -551.
-
Ortiz-Lucas, M., Tobias, A., Saz, P. and Sebastian, J.J., 2013. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Revista Espanola de Enfermedades Digestivas 105: 19-36.
'Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis ' () 105 Revista Espanola de Enfermedades Digestivas : 19 -36.
-
Peery, A.F., Dellon, E.S., Lund, J., Crockett, S.D., McGowan, C.E., Bulsiewicz, W.J., Gangarosa, L.M., Thiny, M.T., Stizenberg, K., Morgan, D.R., Ringel, Y., Kim, H.P., Dibonaventura, M.D., Carroll, C.F., Allen, J.K., Cook, S.F., Sandler, R.S., Kappelman, M.D. and Shaheen, N.J., 2012. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143: 1179-1187.
'Burden of gastrointestinal disease in the United States: 2012 update ' () 143 Gastroenterology : 1179 -1187.
-
Sampalis, J., Psaradellis, E. and Rampakakis, E., 2010. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study. Archives of Medical Science 6: 56-64.
'Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study ' () 6 Archives of Medical Science : 56 -64.
-
Shih, D.Q. and Kwan, L.Y., 2007. All roads lead to Rome: update on Rome III criteria and new treatment options. Gastroenterology Report 1: 56-65.
'All roads lead to Rome: update on Rome III criteria and new treatment options ' () 1 Gastroenterology Report : 56 -65.
-
Somberg, J.C., 2012. The human microbiome and therapeutics. American Journal of Therapeutics 19: 247.
'The human microbiome and therapeutics ' () 19 American Journal of Therapeutics : 247.
-
Tack, J., Müller-Lissner, S., Bytzer, P., Corinaldesi, R., Chang, L., Viegas, A., Schnekenbuehl, S., Dunger-Baldauf, C. and Rueegg, P., 2005. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 54: 1707-1713.
'A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation ' () 54 Gut : 1707 -1713.
-
U.S. Department of Health and Human Services (USDHHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), 2012. Guidance for industry: irritable bowel syndrome – clinical evaluation of drugs for treatment. CDER, Silver Spring, MD, USA. Available at: http://tinyurl.com/yby5l2m5.
-
Whelan, K. and Myers, C.E., 2010. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. American Journal of Clinical Nutrition 91: 687-703.
'Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials ' () 91 American Journal of Clinical Nutrition : 687 -703.
-
Yoon, H., Park, Y.S., Lee, D.H., Seo, J.G., Shin, C.M. and Kim, N., 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Biochemistry and Nutrition 57: 129-134.
'Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial ' () 57 Journal of Clinical Biochemistry and Nutrition : 129 -134.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 2127 | 767 | 138 |
| Gesamttextansichten | 58 | 24 | 2 |
| PDF-Downloads | 99 | 47 | 4 |
Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study
in Beneficial MicrobesSearch for other papers by K. Preston in
Current site
Google Scholar
PubMed
Search for other papers by R. Krumian in
Current site
Google Scholar
PubMed
Search for other papers by J. Hattner in
Current site
Google Scholar
PubMed
Search for other papers by D. de Montigny in
Current site
Google Scholar
PubMed
Search for other papers by M. Stewart in
Current site
Google Scholar
PubMed
Search for other papers by S. Gaddam in
Current site
Google Scholar
PubMed
A combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 was compared to placebo for relief of symptoms of irritable bowel syndrome (IBS). A total of 113 subjects at 3 clinical sites were randomised in a 2:1 ratio and followed for 12 weeks. Subjects ingested either 2 capsules of active study product, containing 50×109 cfu of live organisms, or 2 placebo capsules daily. Endpoints included improvement in abdominal pain, days of pain, distention, stool consistency and frequency, quality of life (QOL), and adequate relief (AR) of IBS symptoms. IBS subtypes constipation (IBS-C), diarrhoea (IBS-D), and mixed (IBS-M) were evaluated separately; the effect of gender was also examined. For all efficacy endpoints improvement of 30% or more vs placebo was considered clinically significant. With the exception of pain intensity and AR, the endpoints demonstrated a therapeutic advantage of active over placebo for IBS symptoms in at least some subject subgroups. The IBS-D and female subgroups showed the largest and most consistent effects. Stool frequency and consistency were evaluated in the IBS-C and IBS-D subgroups, and improvement of active vs placebo was noted in both. QOL improvement was seen overall and in specific domains. Adverse events (AEs) were limited to 7 subjects; all were of mild or moderate intensity except one, severe cramping. Four AEs in the same subject in the placebo group were judged to be related to study product; these resolved by the end of study. There were no serious AEs.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 2127 | 767 | 138 |
| Gesamttextansichten | 58 | 24 | 2 |
| PDF-Downloads | 99 | 47 | 4 |
